These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 30267861

  • 1. Young Adults With Esophageal Adenocarcinoma Present With More Advanced Stage Tumors and Have Shorter Survival Times.
    Sawas T, Manrique GC, Iyer PG, Wang KK, Katzka DA.
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1756-1762. PubMed ID: 30267861
    [Abstract] [Full Text] [Related]

  • 2. Clinical characteristics of young patients with early Barrett's neoplasia.
    Iwaya Y, Shimamura Y, Goda K, Rodríguez de Santiago E, Coneys JG, Mosko JD, Kandel G, Kortan P, May G, Marcon N, Teshima C.
    World J Gastroenterol; 2019 Jun 28; 25(24):3069-3078. PubMed ID: 31293342
    [Abstract] [Full Text] [Related]

  • 3. Is Barrett's metaplasia the source of adenocarcinomas of the cardia?
    Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M, Hinder RA, Bremner CG, DeMeester TR.
    Arch Surg; 1994 Jun 28; 129(6):609-14. PubMed ID: 8204035
    [Abstract] [Full Text] [Related]

  • 4. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S, Vennalaganti S, Gaddam S, Vennalaganti P, Young P, Gupta N, Thota P, Cash B, Mathur S, Sampliner R, Moawad F, Lieberman D, Bansal A, Kennedy KF, Vargo J, Falk G, Spaander M, Bruno M, Sharma P.
    Gastroenterology; 2018 Apr 28; 154(5):1282-1289.e2. PubMed ID: 29273452
    [Abstract] [Full Text] [Related]

  • 5. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
    Agoston AT, Zheng Y, Bueno R, Lauwers GY, Odze RD, Srivastava A.
    Am J Surg Pathol; 2015 Aug 28; 39(8):1085-92. PubMed ID: 26076061
    [Abstract] [Full Text] [Related]

  • 6. [Adenocarcinoma of the esophagogastric junction: association with Barrett esophagus and gastroesophageal reflux--surgical results in 122 patients].
    Schumpelick V, Dreuw B, Ophoff K, Fass J.
    Leber Magen Darm; 1996 Mar 28; 26(2):75-6, 79-80, 83-6. PubMed ID: 8684248
    [Abstract] [Full Text] [Related]

  • 7. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J.
    Strahlenther Onkol; 2018 Feb 28; 194(2):125-135. PubMed ID: 29071366
    [Abstract] [Full Text] [Related]

  • 8. Validation of Tools for Predicting Incident Adenocarcinoma of the Esophagus or Esophagogastric Junction.
    Rubenstein JH, Raghunathan T, Doan C, Schneider J, Zhao W, Metko V, Nofz K, Khodadost M, Corley DA.
    Am J Gastroenterol; 2021 May 01; 116(5):949-957. PubMed ID: 33852454
    [Abstract] [Full Text] [Related]

  • 9. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma.
    Matsuno K, Ishihara R, Ohmori M, Iwagami H, Shichijyo S, Maekawa A, Kanesaka T, Yamamoto S, Takeuchi Y, Higashino K, Uedo N, Matsunaga T, Morishima T, Miyashiro I.
    J Gastroenterol; 2019 Sep 01; 54(9):784-791. PubMed ID: 30927083
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades.
    Sawas T, Azad N, Killcoyne S, Iyer PG, Wang KK, Fitzgerald RC, Katzka DA.
    Clin Gastroenterol Hepatol; 2020 Nov 01; 18(12):2710-2716.e1. PubMed ID: 31712077
    [Abstract] [Full Text] [Related]

  • 11. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R.
    Cancer; 2007 Feb 15; 109(4):668-74. PubMed ID: 17211862
    [Abstract] [Full Text] [Related]

  • 12. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
    Lada MJ, Nieman DR, Han M, Timratana P, Alsalahi O, Peyre CG, Jones CE, Watson TJ, Peters JH.
    Surgery; 2013 Oct 15; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Patients with esophageal adenocarcinoma showed better prognosis than those with adenocarcinoma of the gastroesophageal junction.
    Huang Q, Cheng Y, Lew E, Shi J, Wiener D, Weber HC.
    J Dig Dis; 2023 Feb 15; 24(2):98-112. PubMed ID: 36970757
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa.
    Portale G, Peters JH, Hagen JA, Demeester SR, Gandamihardja TA, Tharavej C, Hsieh CC, Demeester TR.
    Arch Surg; 2005 Jun 15; 140(6):570-4; discussion 574-5. PubMed ID: 15967904
    [Abstract] [Full Text] [Related]

  • 20. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma.
    Hammad TA, Thrift AP, El-Serag HB, Husain NS.
    Dig Dis Sci; 2019 Feb 15; 64(2):367-372. PubMed ID: 30370493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.